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The potential therapeutic activity of a human monoclonal antibody to the human interleukin-12 p40 subunit (anti-IL-
12p40) has been established both in vitro and in vivo, warranting a ﬁrst-in-human investigation in psoriasis. This
phase I, ﬁrst-in-human, non-randomized, open-label study evaluated the short-term safety, pharmacokinetics, and
clinical response of single, ascending, intravenous (IV) doses of anti-IL-12p40 in subjects with moderate-to-severe
psoriasis vulgaris. Eighteen subjects with at least 3% body surface area involvement were enrolled in four dose
groups (0.1, 0.3, 1.0, and 5.0 mg per kg). Safety, pharmacokinetics, and clinical response (e.g., Psoriasis Area and
Severity Index (PASI)) were monitored at baseline and at specific time points over a 16-wk follow-up period. Anti-IL-
12p40 was generally well tolerated. No related serious adverse events or infusion reactions were reported, and
most adverse events were mild. IV anti-IL-12p40 yielded linear pharmacokinetics, with a mean terminal half-life of
approximately 24 d. Dose-dependent associations with both the rate and extent of clinical response were observed
across the four dose groups. Twelve of 18 subjects (67%) achieved at least a 75% improvement in PASI between 8
and 16 wk after study agent administration. Significant and sustained concentration-dependent improvements in
psoriatic lesions were observed in most subjects.
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Psoriasis vulgaris is one of the most common human skin
diseases, affecting 1%–3% of the general population
(Greaves and Weinstein, 1995). Psoriasis is a complex dis-
order, which was initially characterized by inflammation,
keratinocyte hyperproliferation, and decreased epidermal
differentiation (Christophers and Sterry, 1993). More recent-
ly, substantial evidence indicates that T lymphocytes,
specifically the type 1 T helper cell (Th1) subtype, ma-
crophages, and certain cytokines play a pivotal role in the
pathogenesis of the disease (Barker et al, 1991; Boyman
et al, 2004). The significant role of Tcells is demonstrated by
the fact that transplantation of bone marrow from a psoriatic
donor induces the disease in recipients, whereas trans-
plantation of bone marrow from a non-diseased donor to
a recipient with psoriasis is curative (Jowitt and Yin, 1990;
Kanamori et al, 2002). Furthermore, systemic agents such
as cyclosporin A and methotrexate have been known to
inhibit T cell function and/or proliferation and suppress
psoriatic disease. Although these agents are effective, po-
tential renal, hepatic, and pulmonary toxicity limits their use
(Greaves and Weinstein, 1995; Griffiths et al, 1995). This has
spurred the development of new biologic therapies (i.e.,
monoclonal antibodies and fusion proteins) that selectively
target key cytokines and receptor molecules in the T cell-
mediated inflammatory process rather than providing
generalized immunosuppression associated with previous
therapies (Chaudhari et al, 2001; Papp et al, 2001; Krueger,
2002; Gordon et al, 2003; Gottlieb et al, 2003; Lebwohl et al,
2003; Leonardi et al, 2003).
Two cytokines that are thought to be important in the
development of Th1 immune responses in psoriasis are in-
terleukin-12 (IL-12) and IL-23. Both cytokines are produced
by antigen-presenting cells, such as macrophages and
dendritic cells, and function by activating T cells and natural
killer cells. IL-12 and IL-23 are members of a heterodimeric
family of soluble cytokines that are comprised of p35/p40
protein subunits in IL-12 and p19/p40 protein subunits in IL-
23. The IL-12 p40 subunit of either cytokine will bind to the
transmembrane IL-12 receptor b 1 (IL-12Rb1) that is found
on the surface of immune cells.
Abbreviations: Anti-IL-12p40, antibody to interleukin-12 p40 sub-
unit; AUC, area under the curve; BSA, body surface area; Cmax,
maximum serum concentration; ELISA, enzymed-linked immuno-
sorbant assay; IFN, interferon; IL, interleukin; IV, intravenous;
LLOQ, lower limit of quantification; PASI, psoriasis area and se-
verity index; PGA, physician’s global assessment; t1/2, terminal
half-life; Th1, type 1 T helper
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Subsequent binding of IL-12 p35 or IL-23 p19 to their
receptor partners, IL-12Rb2 and IL-23R, respectively, re-
sults in immune signaling events that are specific for each
cytokine. Thus, interruption of the IL-12 p40/IL-12Rb1 in-
teraction will prevent the biological activity of both IL-12 and
IL-23. The functions of IL-12 have been well characterized
and include induction of interferon-g (IFN-g), differentiation
of Th1 cells, and bridging between innate resistance and
adaptive immunity (Trinchieri, 2003). Although many of the
immune consequences of IL-23 are still the subject of active
research, IL-23 has been proposed to have functions that
are similar, but not identical, to those of IL-12 (Oppmann
et al, 2000).
A growing body of scientific evidence suggests that both
IL-12 and IL-23 may contribute to the underlying patholog-
ical processes associated with psoriasis. IL-12 p40 and
IFN-g protein and mRNA are markedly increased in psoriatic
skin lesions, but not in adjacent normal skin, and are pre-
dominately expressed on mononuclear cells in the dermis
(Yawalkar et al, 1998). In a study of patients with psoriasis, it
was shown that IL-12 p40 and IL-23 p19 gene expression
was greatly increased in psoriatic skin lesions, whereas
there was no increase in IL-12 p35 expression (Lee et al,
2004). In a transgenic mouse that overexpressed IL-12 p40,
it was shown that IL-23, but not IL-12, was constitutively
produced by basal keratinocytes (Kopp et al, 2003). Since
keratinocytes are thought to be a key participant in psoria-
sis pathobiology, IL-23 production may provide a molecular
explanation for their involvement. Collectively, these data
support the potential contribution of IL-23 to the patho-
physiology of psoriasis. A murine model of psoriasis dem-
onstrated the appropriateness of IL-12 and IL-23 as
therapeutic targets. A neutralizing antibody to IL-12 p40
successfully abolished psoriatic lesions in mice, even when
administered after transfer of the T cell subset that induced
the psoriasis-like condition (Hong et al, 1999). Therefore,
pre-clinical analyses support the clinical investigation of IL-
12 and IL-23 neutralization using an antibody to the human
interleukin-12 p40 subunit (anti-IL-12p40) in subjects with
psoriasis.
Non-clinical toxicology studies with anti-IL-12p40 ad-
ministered intravenously (IV) or subcutaneously to cyno-
molgus monkeys have been conducted. Anti-IL-12p40 was
administered IV once weekly for a month or subcutaneously
twice weekly for 6 mo at doses up to 50 mg per kg. Anti-
ILp40 was well tolerated in all of the multi-dose toxicity
studies in monkeys given IV or subcutaneous doses up to
50 mg per kg. No overt signs of toxicity were observed.
Minimal signs of local irritation were observed in some an-
imals injected with multiple subcutaneous doses of anti-
IL12p40. IV and subcutaneous dose embryo-fetal toxicity
studies were performed in monkeys to support IV dose ad-
ministration of anti-IL12p40 to women of childbearing po-
tential. No maternal or fetal abnormalities were observed
following doses up to 50 mg per kg administered during the
period of organogenesis. An additional study was conduct-
ed in a monkey asthma model to determine if administration
of anti-IL-12 would exacerbate induced asthmatic effects.
Results showed that anti-IL-12p40 did not exacerbate the
pulmonary function of the study monkeys following two IV
50 mg per kg doses administered 4 wk apart.
Anti-IL12p40 is a human IgG1 k monoclonal antibody
that binds to the p40 subunit of human IL-12 and IL-23 and
prevents its interaction with IL-12Rb1. Therefore, anti-IL-
12p40 neutralizes IL-12 bioactivity, as measured by the
inhibition of IFN-g production from mitogen-stimulated
CD3þ T-lymphocytes (Brok et al, 2002; Cua et al, 2003).
In vivo administration of anti-IL-12p40 inhibited the devel-
opment of neurologic dysfunction and neuropathological
changes in a marmoset model for multiple sclerosis, which
like psoriasis, is considered to be a Th1-associated auto-
immune disease with a strong contribution from IL-12 and
IL-23 (Brok et al, 2002). Therefore, the potential therapeutic
activity of anti-IL-12p40 that had been established in vitro
and in vivo warranted a first-in-human investigation in a
psoriasis population. The primary objectives of this phase I
study were to evaluate the short-term safety, assess the
pharmacokinetics, and determine the clinical response of
single, ascending, IV administrations of anti-IL-12p40 in
subjects with moderate-to-severe psoriasis vulgaris.
Results
Demographic and baseline disease characteristics The
demographic and baseline disease characteristics for the
study population are shown in Table I. All 18 subjects who
participated in the study were evaluable, having received
the scheduled single-dose infusion of anti-IL-12p40 and
completed the scheduled follow-up visits; no subject dis-
continued study agent infusion. The dose groups were
comparable with respect to demographics and baseline
disease characteristics. A predominance of men (14 of 18
subjects; 78%) enrolled in the study, primarily because of
the exclusion of women of childbearing potential. The dose
groups were generally comparable in relation to the duration
and extent of disease, considering the small number of
subjects in each group. The minimal duration of psoriasis
was 3.4 y, with a mean duration range of 13.6–19.7 y across
the four dose groups. Baseline BSA of plaque psoriasis in-
volvement ranged from 3.0% to 35.0%, and baseline PASI
ranged from 5.6 to 34.8.
Safety No treatment-related serious adverse events were
reported. One subject in the 5.0 mg per kg dose group
experienced a serious adverse event that the investigator
considered not related to study drug. This subject had a
pre-existing disc disease and had undergone laminectomy
and partial discectomy approximately 6 mo before receiving
study agent. The back pain worsened approximately 11 wk
after receiving study agent, and an additional laminectomy
and discectomy was performed approximately 2 wk later.
This event was continuing at the end of the study.
All subjects experienced at least one adverse event dur-
ing the 16-wk study, but there was no evidence of a rela-
tionship between dose and response in intensity, duration,
or frequency of adverse events. The majority of adverse
events were mild in intensity. There were no adverse events
suggestive of infusion reactions or immediate or delayed
hypersensitivity responses to the study drug. No adverse
events resulted in either discontinuation or reduction in
the dose of the study agent. The most commonly reported
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adverse events included decreases in T-lymphocyte sub-
sets (10 subjects), headache (six subjects), common cold
symptoms (five subjects), and pain at the biopsy site (four
subjects). The majority of specific adverse events occurred
in only one or two of the 18 subjects.
The majority of adverse events were not considered to
be related to study agent by the investigators; however,
because of the potential role of IL-12 in Th1 differentiation
and natural killer cell cytolytic activity, asymptomatic de-
creases in the counts of CD4þ (the surface marker for
T helper cells) or CD16þ /CD56þ (natural killer cells) were
identified by the investigators as adverse events considered
probably or definitely related to study agent administration
(Abbas et al, 2000). Transient decreases in the numbers of
CD4þ and CD16þ /56þ cells were observed in some
subjects, but the degree and duration of such decreases
were highly variable across the four dose groups (Fig 1). A
decrease in the number of CD4þ cells was observed in
some subjects between 24 and 72 h after study agent ad-
ministration, with a return to baseline levels between 1 and
12 wk after study drug administration. In two subjects, the
CD4þ counts were below 400 cells per mm3 for a period of
5 d, with nadirs of 369 and 356 cells per mm3, respectively.
No relationship between decreases in either CD4þ or
CD16þ /56þ cells and dose was observed and no varia-
tions in the numbers of CD3þ , CD19þ , CD8þ , or CD4þ /
CD8þ populations were detected.
The long half-life of anti-IL-12p40 limited the extent to
which the development of antibodies to the anti-IL-12p40
could be evaluated in this study. Of the 18 enrolled subjects,
however, one subject (0.1 mg per kg dose group) demon-
strated a 1:80 titer at 16 wk after study agent administration.
The antibodies were specific for the study agent, since pre-
incubation of the serum with the anti-IL12p40 completely
neutralized the assay reactivity. The development of anti-
bodies to anti-IL-12p40 in this subject was not associated
with any adverse events likely to be related to the immune
response. Another subject (0.1 mg per kg dose group) was
confirmed to be negative for antibodies to study agent. An-
tibody determinations were considered inconclusive in the
remaining 16 subjects because anti-IL-12p40, which inter-
feres with the in vitro assay, was present in all post-dose
serum specimens.
Pharmacokinetics The mean serum concentration–time
profiles of anti-IL-12p40 are shown for each treatment
group in Fig 2. Anti-IL-12p40 demonstrated linear phar-
macokinetics over the dose range evaluated. Dose-propor-
tional increases in maximum serum concentration (Cmax)
were observed. Across the four dose groups, the Cmax
(mean  SD) ranged from 3.0  0.6 mg per mL (0.1 mg per
kg dose group) to 152.0  19.1 mg per mL (5.0 mg per kg
dose group). The t1/2 (mean  SD) was 27.0  7.5, 18.5 
3.6, 25.9  3.7, and 23.7  5.7 d in the 0.1, 0.3, 1.0, and 5.0
mg per kg, dose groups respectively, indicating similar
elimination rates with all doses. The AUC (mean  SD) in-
creased linearly with the dose, ranging from 53.6  8.9
mg d per mL in the 0.1 mg per kg dose group to
2607.5  398.9 mg d per mL in the 5.0 mg per kg dose
group.
Clinical response The clinical response profile, as meas-
ured by the change in PASI from baseline, for the four anti-
IL-12p40 dose groups is shown in Fig 3. In the 0.1 mg per
kg group, three of four subjects (75%) reported at least a
50% improvement in PASI by week 8 (Fig 3A). One of these
subjects (25%) achieved at least a 75% reduction in PASI
score by week 8, a response that was maintained through
week 16. In the 0.3 mg per kg dose group, two of four
subjects (50%) exhibited at least a 75% reduction in PASI
score by week 12 (Fig 3B), which was sustained through
week 16; however, the two subjects in the 0.3 mg per kg
dose group who had the highest baseline PASI scores (i.e.,
21.3 and 34.8) did not exhibit a significant clearing in their
psoriatic plaques. In the 1.0 mg per kg dose group, all five
subjects (100%) achieved at least a 50% improvement in
PASI score by week 8. Three of five subjects (60%) and four
of five subjects (80%) reported a minimum or greater than
75% reduction in PASI score by weeks 12 and 16, respec-
tively (Fig 3C). In the 5.0 mg per kg group, three of five
subjects (60%) reported at least a 50% improvement in
PASI at week 4, with one subject achieving at least a 75%
improvement. All five subjects (100%) achieved at least a
75% reduction in PASI score by week 12, a response that
was sustained through week 16 (Fig 3D). Figure 4 shows
psoriasis activity before and at various time points after
Table I. Demographics
Dose groups
(mg per kg)
0.1 0.3 1.0 5.0
Number of
subjects
4 4 5 5
Age (years)
Mean 37.5 40.0 42.8 42.8
Range 23–51 30–52 32–54 31–55
Gender
Male 4 2 5 3
Female 0 2 0 2
Weight (kg)
Mean 95.3 93.2 99.4 84.6
Range 69.1–140.5 70.0–127.3 68.9–110.9 65.5–131.8
Baseline PASI
Median 11.0 18.2 14.7 13.6
Range 5.8–13.1 8.8–34.8 7.4–15.8 5.6–27.8
% BSA
Mean 10.9 15.0 9.4 11.6
Range 6.5–15 7.0–20.0 4.0–16.0 3.0–35.0
Duration of psoriasis (years)
Mean 13.6 16.9 16.6 19.7
Range 3.4–20.2 11.5–25.2 7.6–30.8 9.0–42.0
PASI, psoriasis area and severity index; BSA, body surface area.
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treatment with anti-IL-12p40 in subjects from different dose
groups.
Results for clinical response as measured by PGA scores
showed that, by week 2, at least one subject in each treat-
ment group achieved mild or better PGA scores. All sub-
jects in the 1.0 and 5.0 mg per kg groups achieved mild or
better PGA scores at weeks 12 and 16 compared with
75.0% and 50.0% of subjects in the 0.1 and 0.3 mg per kg
groups, respectively, at both of these time points. The rel-
ative improvement in PASI and PGA scores for each dose
group is shown in Table II. At week 16, a clear correlation
was observed between the anti-IL-12p40 dose and the
proportion of subjects achieving at least a 75% improve-
ment in PASI score or a minimal or better PGA score, both
of which are indicative of clinically meaningful improvement.
Discussion
The purpose of this phase I clinical trial was to determine
the short-term safety, pharmacokinetics, and clinical re-
sponse of anti-IL-12p40 in subjects with moderate-to-se-
vere plaque psoriasis. The majority of subjects in this study
had a long history of disease, with the mean duration rang-
ing from 13.6 to 19.7 y across treatment groups. Subjects
were administered single IV doses of anti-IL-12p40, ranging
from 0.1 to 5.0 mg per kg, which spanned an estimated
subtherapeutic to therapeutic concentration range. This
range was derived from in vitro and animal studies that in-
cluded careful evaluation of toxicity and efficacy.
This study demonstrated that single IV administrations of
anti-IL-12p40 at different doses were well tolerated in sub-
jects with moderate-to-severe plaque psoriasis. No treat-
ment-related serious adverse events or adverse events
requiring discontinuation or dose reduction were reported in
the study. Most adverse events were mild in severity and
considered not related to study agent administration by in-
vestigators. No dose–response with relation to the intensity,
duration, or frequency of any adverse event was apparent.
No adverse events suggestive of infusion reactions and no
immediate or delayed hypersensitivity responses to study
agent were reported. Transient decreases in peripheral
CD4þ and CD16þ /56þ cells were observed in some
subjects after a single IV administration of study drug, but
values for these parameters were highly variable over time
and dose and did not correlate with any clinical symptoms.
Pharmacokinetic evaluations following IV administration
of a single IV dose of anti-IL-12p40, ranging from 0.1 to 5.0
mg per kg, yielded linear pharmacokinetics, with a mean
terminal half-life (t1/2) of approximately 24 d and a dose-
proportional increase in the Cmax and systemic exposure
(AUC) of anti-IL-12p40.
Of the 18 subjects tested, immunogenicity status (i.e.,
development of antibodies to IL-12 p40) was inconclusive in
16 subjects and negative and positive in one subject each
(both 0.1 mg per kg) at 16 wk following study agent infusion.
The immune response was specific for anti-IL-12p40, as
characterized by complete neutralization of immune re-
sponse activity in the enzyme-linked immunosorbent assay
Figure 1
Percent change from baseline CD4þ and CD16þ /56þ cell
counts. The mean percent from baseline CD4þ (A) and CD16þ /
56þ (B) peripheral blood cell counts for each dose group are plotted
over the 16 wk evaluation period. (’) 0.1 mg per kg dose group; (&)
0.3 mg per kg dose group; (  ) 1.0 mg per kg dose group; (  ) 5.0 mg
per kg dose group.
Figure2
Mean (  SD) serum concentration versus time profiles of the an-
tibody to interleukin-12 p40 subunit (anti-IL-12p40) antibody fol-
lowing single intravenous infusions. (’) 0.1 mg per kg dose group;
(&) 0.3 mg per kg dose group; (  ) 1.0 mg per kg dose group; (  ) 5.0
mg per kg dose group.
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(ELISA) following pre-incubation of the serum sample with
excess anti-IL-12p40. The clearance rate of anti-IL-12p40
for the individual who tested positive was similar to that for
other subjects in the same dose group. Although the con-
sistent elimination rate of anti-IL-12p40 in nearly all subjects
suggests the absence of a significant immune response, the
high number of inconclusive determinations precludes mak-
ing any firm conclusion about the antigenicity of IV anti-IL-
12p40.
The significant and sustained concentration-dependent
improvements in psoriasis were consistent across two clin-
ical response measurements (PASI and PGA) and were
observed in the majority of subjects, which supports the
efficacy of anti-IL-12p40 in psoriasis. Overall, 83% and
67% of subjects, respectively, exhibited at least a 50% and
75% improvement in PASI score during the 16-wk evalu-
ation period. All 10 subjects in the 1.0 and 5.0 mg per kg
groups and two subjects each in the 0.1 and 0.3 mg per kg
groups achieved PGA scores of minimal or better by week
16. The 0.3 mg per kg dose may have been subtherapeutic
in the two subjects with the more severe disease (baseline
PASI scores of 21.3 and 34.8) who did not exhibit significant
clearing by week 16, as further shown by the subject with
the highest baseline PASI score (27.8) in the 5.0 mg per kg
group who achieved clearing at the higher dose. Concen-
tration-dependent improvements in both the rate and extent
of therapeutic benefit were observed across the four dose
groups. Noticeable clearing of psoriatic plaques was ob-
served as early as 2 wk following study agent administra-
tion, with maximal therapeutic benefit achieved at 12 wk for
the majority of subjects. In addition, therapeutic benefit was
sustained throughout the 16-wk evaluation period in sub-
jects who achieved at least a 75% improvement in PASI
scores.
This is the first report of human data suggesting that IL-
12 p40 is an appropriate therapeutic target for subjects with
psoriasis. IL-12 p40 and IL-23 p19 gene expression has
been reported in psoriatic plaques (Yawalkar et al, 1998; Lee
et al, 2004), and data from murine models has suggested
that neutralization of IL-12 or IL-23 would provide thera-
peutic benefit (Hong et al, 1999; Kopp et al, 2003). The
results presented here, however, are the first to suggest that
neutralization of IL-12 and IL-23 through a fully human
monoclonal antibody to IL-12 p40 provides clinical benefit
in human psoriasis. These results support the strategy of
developing monoclonal antibodies targeted at key cyto-
kines involved in the development of the Th1 immune re-
sponse in autoimmune diseases, such as anti-IL-12p40 in
the case of psoriasis. Furthermore, these results confirm
that the p40 subunit of IL-12 is involved in the underlying
pathogenesis of psoriasis and that developing a monoclonal
antibody to directly target this subunit contributes to the
effectiveness of this biologic.
This study was limited by certain factors related to study
design, subject population, and sampling difficulties. The
study design was open label and lacked a placebo group,
and thus, did not allow a blinded and comparative assess-
ment of clinical response. Furthermore, because this was a
first-in-human study, more subjects with less severe pso-
riasis were allowed than would typically be recruited in
Phase II/III studies of biological therapy. The determination
of immunogenicity was limited in this study because of the
presence of study agent in the circulation of most subjects
throughout the evaluation period. Finally, the small number
of subjects allows only limited early assumptions about the
safety of anti-IL-12p40.
In conclusion, this clinical study provides the first infor-
mation on the safety, pharmacokinetics, and clinical
Figure 3
Percent improvement in baseline pso-
riasis area and severity index (PASI)
scores. The percent improvement in PASI
score for each subject within a dose group
is plotted over the 16 wk evaluation peri-
od. (A) 0.1 mg per kg dose group; (B) 0.3
mg per kg dose group; (C) 1.0 mg per kg
dose group; (D) 5.0 mg per kg dose group.
For reference, the baseline PASI scores for
each subject within a dose group is shown
below each graph.
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response of single IV administrations of anti-IL-12p40 in
human subjects with moderate-to-severe plaque psoriasis.
Anti-IL-12p40 was well tolerated, with no significant safety
concerns, and demonstrated substantial concentration-de-
pendent efficacy. Further evaluation is merited in larger,
randomized, and blinded clinical studies.
Materials and Methods
Study protocol and subject eligibility This clinical study was
conducted at two sites; the PAREXEL-Baltimore Clinical Pharma-
cology Research Unit and the Clinical Research Center at the Uni-
versity of Medicine and Dentistry of New Jersey, Robert Wood
Johnson Medical School. Institutional Review Boards at both sites
approved the study, which was conducted in conformance with the
regulations established for the Protection of Human Subjects (21
Code of Federal Regulations Part 50) and Institutional Review
Boards (21 Code of Federal Regulations Part 56), in accordance
with Good Clinical Practices, and in compliance with local regu-
lations. Subjects were recruited through general advertising, and
all subjects provided written informed consent prior to the per-
formance of any study-specific procedures.
Men and women in general good health and between the ages
of 18 and 65 y were eligible to participate in this study. Female
subjects were either postmenopausal (no menstrual period for a
minimum of 1 y) or surgically sterilized; subjects were required to
have a negative serum pregnancy test at study entry. To minimize
the possibility of indirect exposure to anti-IL-12p40, male subjects
agreed to use adequate contraceptives during the study and for
6 mo after study drug administration. Subjects had chronic mod-
erate-to-severe plaque psoriasis involving at least 3% body surface
area (BSA) and at least two plaques located on either the trunk or
extremities, with a confirmed diagnosis at least 6 mo prior to
Figure 4
Psoriasis activity before and af-
ter treatment with antibody to
interleukin-12 p40 subunit. 0.1
mg per kg dose (1 wk post-treat-
ment [baseline not available] and
16 wk post-treatment); 0.3 mg per
kg dose (baseline and 16 wk post-
treatment); 1.0 mg per kg dose
(baseline and 16 wk post-treat-
ment); 1.0 mg per kg (baseline and
8 wk post-treatment); 5.0 mg per
kg dose (baseline and 8 wk post-
treatment); 5.0 mg per kg (base-
line, and 4, 8 and 16 wk post-
treatment).
Table II. Improvement in PASI and PGA scores through week 16
Dose group
Number of
subjects achieving
at least a 75%
improvement in
PASI score
Number of
subjects achieving
minimal or
better PGA score
0.1 mg per kg (n¼4) 1 2
0.3 mg per kg (n¼4) 2 2
1.0 mg per kg (n¼5) 4 3
5.0 mg per kg (n¼5) 5 4
PASI, psoriasis area and severity index; PGA, physician’s global as-
sessment.
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screening. In an effort to expedite study enrollment, the study pro-
tocol was amended to decrease the original study entry criteria of at
least 5% BSA of plaque psoriasis involvement to at least 3% BSA.
A chest X-ray was required within 1 y of study agent admin-
istration to exclude subjects with malignancy, infection, fibrosis, or
past/current tuberculosis infection.
Subjects were excluded from participating in the study if they
had any serious systemic or local infection within 3 mo before
screening, a history or any signs of lymphoproliferative disease, or
a known malignancy or a history of malignancy within the previous
5 y (with the exception of basal cell or squamous cell carcinoma of
the skin that had been fully excised with no evidence of recur-
rence). Participants had to have a medical history negative for al-
cohol or substance abuse within the previous 6 mo and had to
have negative test results for HIV, hepatitis B, hepatitis C prior to
enrollment.
Subjects could not have received previous treatment with
monoclonal antibodies or antibody fragments or any previous
treatment with a non-monoclonal antibody/non-immunoglobulin
investigational drug within 28 d prior to infusion of study agent. All
systemic psoriasis medications, including psoralen long-wave ul-
traviolet radiation treatments, or other systemic immunosuppress-
ives were prohibited within 4 wk before the study drug
administration. The use of single-treatment phototherapy (ultravi-
olet B or self-treatment with tanning beds) was not allowed within
14 d prior to the study drug administration and the use of topical
therapy for psoriasis was prohibited within 7 d prior to the study
agent administration. The only medications allowed during the
study were lipid-lowering drugs, anti-hypertensives, oral medica-
tions for type II diabetes, estrogen replacement therapy, thyroid
replacement therapy, antihistamines used for pruritus, antacids,
histamine H2-receptor antagonists, and proton pump inhibitors;
subjects taking these medications were required to have been on
chronic stable doses prior to screening.
The study was a phase I, first-in-human, non-randomized,
open-label, single administration, dose-escalating study of anti-IL-
12p40, designed to evaluate the safety, pharmacokinetics, and
clinical response in subjects with moderate-to-severe psoriasis.
Each subject received a single IV infusion of study drug. The dose
groups were as follows: 0.1 mg per kg (n¼ 4), 0.3 mg per kg (n¼ 4),
1.0 mg per kg (n¼ 5), and 5.0 mg per kg (n¼ 5). For each subject,
anti-IL-12p40 was administered by infusion over a minimum of 120
min. As a safety precaution, subsequent subjects within each dose
group were not administered anti-IL-12p40 for at least 48 h after
the first subject had received the study medication. The duration of
safety follow-up for each subject was 16 wk after administration of
the study agent.
Study procedures
Safety assessments The safety and tolerability of anti-IL-12p40
were assessed by monitoring the occurrence of adverse events or
abnormalities identified by standard laboratory tests, vital sign
measurements, and physical examinations. Laboratory tests per-
formed at each visit included complete blood count with differential
and platelet count, lymphocyte subset analyses, serum chemis-
tries, prothrombin time, and partial thromboplastin time. Lymph-
ocyte subset analyses and other laboratory tests were performed
using standard methodology at MedStar Research Institute (Wash-
ington, District of Columbia). To ensure reliable test results, study
personnel were given specific instructions for sample handling.
Assessments of antibody production to anti-IL-12p40 Serum sam-
ples for immune response assessments were obtained prior to in-
fusion and at 2, 8, and 16 wk after infusion of the study agent, anti-
IL12p40. The development of an antibody response to anti-IL-
12p40 was measured using an antigen bridging enzyme immuno-
assay in which serum samples were added to an anti-IL-12p40-
coated plate. Antibodies in the serum that bind to anti-IL-12p40
were then detected by adding exogenous study agent that was
previously biotinylated anti-IL-12p40. Thus, samples that contain
antibodies to anti-IL-12p40 will be detected by streptavidin reac-
tivity. Subjects were designated immune response positive if an-
tibodies to study agent were detected at any time point following
infusion. Subjects were designated as immune response negative
if they did not demonstrate antibodies to anti-IL-12p40 at any time
point following infusion and if the study agent was not detectable in
serum. If subjects had no response in the antigen bridging assay,
yet had measurable levels of anti-IL-12p40 in their serum, they
were designated as immune-response inconclusive. The presence
of study agent in the antigen-bridging assay characteristically in-
terferes with the detection of an antibody immune response be-
cause both arms of the immunoglobulin must be available to bind
the antigen coated on the plate, as well as the streptavidin-con-
jugated antigen.
Pharmacokinetic assessments Serum samples for pharmacokinet-
ic assessments were obtained at baseline, 1 h after the start of
infusion, at the end of infusion (2 h), and at 4, 24, 48, and 72 h after
the start of infusion of the study agent. Subsequent serum samples
were collected at 1, 2, 4, 8, 12, and 16 wk following the study agent
administration. Serum anti-IL-12p40 levels were measured using a
validated ELISA with a lower limit of quantification (LLOQ) of 0.1 mg
per mL following a 10-fold dilution. Pharmacokinetic parameters,
including Cmax, t1/2, and AUC, were derived from non-compart-
mental analysis.
Clinical response assessments Clinical response measurements
(PASI and PGA), were performed at baseline, 72 h, and at 1, 2, 4, 8,
12, and 16 wk after administration of study agent. PASI, a system
used for grading the severity of psoriatic lesions and their response
to therapy, produces a numeric score ranging from 0 to 72 based
on the rating of erythema, thickness, and scaling on the head,
trunk, and upper and lower extremities (Fredriksson and Petters-
son, 1978). PGA is an overall assessment of a patient’s psoriasis,
based on four signs of disease (severity, thickness, scaling, and
erythema) as rated on a scale of 0–5. To reduce inter-rater vari-
ability, every effort was made to avoid having more than one as-
sessor perform the PASI and PGA measurements for each subject.
To complement PASI and PGA assessments, digital images were
collected for all subjects enrolled in the study. Multiple predefined
views were collected with variables, such as lighting, framing,
background, exposure, and reproduction ratios, held constant to
ensure that the skin was the only variable changing within the im-
age over time. Although pharmacodynamic measurements were
performed on biopsied tissue from designated target lesions, the
pharmacodynamic results are not presented in this paper.
Statistical methods Because this was a phase I, first-in-human,
non-randomized, open-label study, no interim analysis or formal
hypothesis testing was conducted and no formal sample size de-
terminations were undertaken. The sample size was small because
the study was conducted to provide preliminary safety assess-
ments of single infusion regimens of anti-IL-12p40. Continuous
variables were summarized using descriptive statistics (e.g.,
number of observations, means, medians, standard deviations,
and ranges) and discrete variables were summarized using fre-
quencies and percentages.
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